Premium
Genotypic and phenotypic characterization of Bordetella pertussis strains used in different vaccine formulations in Latin America
Author(s) -
Bottero D.,
Gaillard M.E.,
Basile L.A.,
Fritz M.,
Hozbor D.F.
Publication year - 2012
Publication title -
journal of applied microbiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.889
H-Index - 156
eISSN - 1365-2672
pISSN - 1364-5072
DOI - 10.1111/j.1365-2672.2012.05299.x
Subject(s) - bordetella pertussis , biology , pulsed field gel electrophoresis , microbiology and biotechnology , strain (injury) , pertussis toxin , pertussis vaccine , genotype , virology , sequence analysis , genetics , bacteria , immunization , antigen , gene , g protein , receptor , anatomy
Aim: To characterize Bordetella pertussis vaccine strains in comparison with current circulating bacteria. Methods and Results: Genomic and proteomic analyses of Bp 137 were performed in comparison with other vaccine strains used in Latin America ( Bp 509 and Bp 10536) and with the clinical Argentinean isolate Bp 106. Tohama I strain was used as reference strain. Pulse‐field gel electrophoresis (PFGE) and pertussis toxin promoter ( ptx P) sequence analysis revealed that Bp 137 groups with Bp 509 in PFGE group III and contains ptx P2 sequence. Tohama I (group II) and Bp 10536 (group I) contain ptx P1 sequence, while Bp 106 belongs to a different PFGE cluster and contains ptx P3. Surface protein profiles diverged in at least 24 peptide subunits among the studied strains. From these 24 differential proteins, Bp 10536 shared the expression of ten proteins with Tohama I and Bp 509, but only three with Bp 137. In contrast, seven proteins were detected exclusively in Bp 137 and Bp 106. Conclusions: Bp 137 showed more features in common with the clinical isolate Bp 106 than the other vaccine strains here included. Significance and Impact of the Study: The results presented show that the old strains included in vaccines are not all equal among them. These findings together with the data of circulating bacteria should be taken into account to select the best vaccine to be included in a national immunization programme.